Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumabs ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).
Purity:
97.60%
CAS Number:
[347396-82-1]
Target:
VEGFR
T9928
* VAT and and shipping costs not included. Errors and price changes excepted
